IDEAL: Efficacy of Porcine Placental Extracellular Matrix Augmented Plus Standard of Care (SOC) Versus SOC Alone for the Management of Diabetic Foot Ulcers
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- ConvaTec Inc.
- Study ID
- NCT06616844
- Status
- Recruiting
Conditions
- Ulcer
- Wound Heal
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- InnovaMatrix® AC — DEVICESOC plus weekly application of the study device
Study Details
A multi-center, prospective, observer-blinded, randomized controlled clinical trial to evaluate the efficacy of PPECM augmented standard of care versus standard of care alone in the management of hard-to-heal diabetic foot ulcers.
Key Dates
- Start date
- Feb 12, 2025
- Status verified
- Mar 2025
- Primary completion
- Feb 28, 2026
- Completion
- Jul 31, 2026
Study Design
- Enrollment
- 194 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- No Intervention: Standard of Care (SOC)Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; Wound bed debridement, if clinically indicated. Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, Appropriate use of systemic antibiotics.
- Experimental: Standard of Care + InterventionSOC arm with the following modifications: * Consecutive weekly application of PPECM for the 12-week study period. * Subjects will receive no more than 12 applications of PPECM Note: PPECM should be applied after standard wound cleansing and debridement procedures, prior to the application of primary wound dressing, in accordance with the IFU.
Primary Outcome Measure
To determine if PPECM augmented care is superior to SOC in the closure of diabetic foot ulcers at 12 weeks. [ Time Frame: 12 weeks ]
Central Contacts
- Andrew Thomas07767036374
Locations (9)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Angel City Research | Los Angeles | California | 90010 | Felix Sigal, DPM (PRINCIPAL_INVESTIGATOR) |
| Center for Clinical Research | San Francisco | California | 94115 | Alexander Reyzelman (PRINCIPAL_INVESTIGATOR) |
| ILD Research Center | Vista | California | 92081 | Dean Vayser (PRINCIPAL_INVESTIGATOR) |
| Dinamo Research and Diagnostic Center | Hialeah | Florida | 33015 | Ramon Sastre (PRINCIPAL_INVESTIGATOR) |
| Indiana Foot & Ankle | Jasper | Indiana | 47456 | Andrew Rader, DPM (PRINCIPAL_INVESTIGATOR) |
| US-FAS | Hagerstown | Maryland | 21742 | Brandy Grahn (PRINCIPAL_INVESTIGATOR) |
| Boston Medical Center | Boston | Massachusetts | 02118 | Vitaly Volansky (PRINCIPAL_INVESTIGATOR) |
| Northwell Health Comprehensive Wound Healing Center | New Hyde Park | New York | 11042 | Alisha Oropallo (PRINCIPAL_INVESTIGATOR) |
| US-FAS | Raleigh | North Carolina | 27609 | Alan Boehm (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Los Angeles, CA
Related Studies
- Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic WoundsEARLY_PHASE1 · Recruiting · University of California, Irvine · Orange, California
- Feasibility and Effectiveness of a Remote Monitoring Program for the Treatment of Diabetic Foot UlcersRecruiting · Johns Hopkins University · Baltimore, Maryland
- Safety and Efficacy of realSKIN® to Provide Complete Wound Closure of Burn Wounds as an Alternative to AutograftingPHASE3 · Recruiting · XenoTherapeutics, Inc. · Phoenix, Arizona
- Incisional Negative Pressure Wound Therapy to Reduce Infection and Complications in High-Risk FracturesPHASE3 · Recruiting · Major Extremity Trauma Research Consortium · Baltimore, Maryland